PL164128B1 - Sposób wytwarzania srodka do leczenia zapalenia pochwy i rzesistkowicy PL PL - Google Patents

Sposób wytwarzania srodka do leczenia zapalenia pochwy i rzesistkowicy PL PL

Info

Publication number: PL164128B1
Authority: PL; Poland
Prior art keywords: weight; agent; metronidazole; total weight; range
Prior art date: 1989-06-06

Application number

PL90285507A

Other languages

English (en)

Polish (pl)

Other versions

PL285507A1 (en

Inventor

Robert J Borgman

Original Assignee

Curatek Pharmaceuticals Ltd Pa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-06

Filing date

1990-06-06

Publication date

1994-06-30

1990-06-06 Application filed by Curatek Pharmaceuticals Ltd Pa filed Critical Curatek Pharmaceuticals Ltd Pa

1992-01-13 Publication of PL285507A1 publication Critical patent/PL285507A1/xx

1994-06-30 Publication of PL164128B1 publication Critical patent/PL164128B1/pl

Links

238000000034 method Methods 0.000 title claims abstract description 40
230000001580 bacterial effect Effects 0.000 title description 8
239000000203 mixture Substances 0.000 claims abstract description 82
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 69
229960000282 metronidazole Drugs 0.000 claims abstract description 68
208000005448 Trichomonas Infections Diseases 0.000 claims abstract description 19
206010044620 Trichomoniasis Diseases 0.000 claims abstract description 19
239000003795 chemical substances by application Substances 0.000 claims description 62
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
239000007853 buffer solution Substances 0.000 claims description 24
239000000872 buffer Substances 0.000 claims description 21
238000009472 formulation Methods 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 10
239000003755 preservative agent Substances 0.000 claims description 9
230000008569 process Effects 0.000 claims description 9
206010046914 Vaginal infection Diseases 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 8
201000008100 Vaginitis Diseases 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 7
239000007764 o/w emulsion Substances 0.000 claims description 6
239000007762 w/o emulsion Substances 0.000 claims description 6
230000002335 preservative effect Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 2
BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
239000000571 coke Substances 0.000 claims 1
230000007774 longterm Effects 0.000 claims 1
239000011780 sodium chloride Substances 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 62
210000001215 vagina Anatomy 0.000 abstract description 24
229920000642 polymer Polymers 0.000 abstract description 23
229920002125 Sokalan® Polymers 0.000 abstract description 11
208000004926 Bacterial Vaginosis Diseases 0.000 abstract description 9
208000037009 Vaginitis bacterial Diseases 0.000 abstract description 9
230000002209 hydrophobic effect Effects 0.000 abstract description 4
239000003125 aqueous solvent Substances 0.000 abstract description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
239000000499 gel Substances 0.000 description 63
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 29
239000002585 base Substances 0.000 description 29
239000000243 solution Substances 0.000 description 23
125000004432 carbon atom Chemical group C* 0.000 description 17
-1 polyethylene Polymers 0.000 description 17
239000004615 ingredient Substances 0.000 description 16
239000003921 oil Substances 0.000 description 16
239000011734 sodium Substances 0.000 description 16
241000186660 Lactobacillus Species 0.000 description 15
235000019198 oils Nutrition 0.000 description 15
229910052708 sodium Inorganic materials 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
235000011187 glycerol Nutrition 0.000 description 14
230000003139 buffering effect Effects 0.000 description 13
230000000694 effects Effects 0.000 description 13
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 11
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 11
244000005700 microbiome Species 0.000 description 11
239000012071 phase Substances 0.000 description 11
239000007864 aqueous solution Substances 0.000 description 10
239000003814 drug Substances 0.000 description 10
239000002480 mineral oil Substances 0.000 description 10
239000004094 surface-active agent Substances 0.000 description 10
239000000337 buffer salt Substances 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
235000014113 dietary fatty acids Nutrition 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000000194 fatty acid Substances 0.000 description 9
229930195729 fatty acid Natural products 0.000 description 9
235000010446 mineral oil Nutrition 0.000 description 9
238000004448 titration Methods 0.000 description 9
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
150000001412 amines Chemical class 0.000 description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
239000006260 foam Substances 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
239000007787 solid Substances 0.000 description 8
239000000829 suppository Substances 0.000 description 8
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 7
241000894006 Bacteria Species 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
150000001298 alcohols Chemical class 0.000 description 7
210000003756 cervix mucus Anatomy 0.000 description 7
239000000839 emulsion Substances 0.000 description 7
150000004665 fatty acids Chemical class 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
206010046901 vaginal discharge Diseases 0.000 description 7
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 6
239000006071 cream Substances 0.000 description 6
239000012530 fluid Substances 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6
229960002216 methylparaben Drugs 0.000 description 6
235000019271 petrolatum Nutrition 0.000 description 6
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000207201 Gardnerella vaginalis Species 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
229960000541 cetyl alcohol Drugs 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000002674 ointment Substances 0.000 description 5
239000001993 wax Substances 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
239000004166 Lanolin Substances 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
239000004264 Petrolatum Substances 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000003513 alkali Substances 0.000 description 4
239000007900 aqueous suspension Substances 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
239000008119 colloidal silica Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
235000019388 lanolin Nutrition 0.000 description 4
229940039717 lanolin Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000002736 nonionic surfactant Substances 0.000 description 4
229940066842 petrolatum Drugs 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
239000000344 soap Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241000207202 Gardnerella Species 0.000 description 3
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000203736 Mobiluncus Species 0.000 description 3
QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
208000003251 Pruritus Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000008351 acetate buffer Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000002411 adverse Effects 0.000 description 3
125000000129 anionic group Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
150000002191 fatty alcohols Chemical class 0.000 description 3
239000003349 gelling agent Substances 0.000 description 3
230000007803 itching Effects 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000004584 polyacrylic acid Substances 0.000 description 3
239000010695 polyglycol Substances 0.000 description 3
229920000151 polyglycol Polymers 0.000 description 3
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
229960003415 propylparaben Drugs 0.000 description 3
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 3
239000000126 substance Substances 0.000 description 3
150000005846 sugar alcohols Polymers 0.000 description 3
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
241001148471 unidentified anaerobic bacterium Species 0.000 description 3
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
206010018612 Gonorrhoea Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000012868 Overgrowth Diseases 0.000 description 2
241000206591 Peptococcus Species 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
239000002280 amphoteric surfactant Substances 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
235000013871 bee wax Nutrition 0.000 description 2
239000012166 beeswax Substances 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000003093 cationic surfactant Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
GOMCKELMLXHYHH-UHFFFAOYSA-L dipotassium;phthalate Chemical compound [K+].[K+].[O-]C(=O)C1=CC=CC=C1C([O-])=O GOMCKELMLXHYHH-UHFFFAOYSA-L 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
208000001786 gonorrhea Diseases 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
210000003622 mature neutrocyte Anatomy 0.000 description 2
238000002844 melting Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
244000005706 microflora Species 0.000 description 2
230000027939 micturition Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical group OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 2
CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
235000019809 paraffin wax Nutrition 0.000 description 2
230000035515 penetration Effects 0.000 description 2
150000002989 phenols Chemical class 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 2
150000003242 quaternary ammonium salts Chemical class 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000000954 titration curve Methods 0.000 description 2
229940029614 triethanolamine stearate Drugs 0.000 description 2
229940044950 vaginal gel Drugs 0.000 description 2
239000000029 vaginal gel Substances 0.000 description 2
239000006216 vaginal suppository Substances 0.000 description 2
239000000003 vaginal tablet Substances 0.000 description 2
210000003905 vulva Anatomy 0.000 description 2
229930195724 β-lactose Natural products 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
GHQFLMULNSGOAR-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;sodium Chemical compound [Na].OC(=O)C(O)C(O)C(O)=O GHQFLMULNSGOAR-UHFFFAOYSA-N 0.000 description 1
KGULFLCOPRYBEV-KTKRTIGZSA-N 2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCO KGULFLCOPRYBEV-KTKRTIGZSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
241000606125 Bacteroides Species 0.000 description 1
241001148536 Bacteroides sp. Species 0.000 description 1
241000269417 Bufo Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
206010064525 Chlamydial cervicitis Diseases 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010010947 Coordination abnormal Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000004483 Dyspareunia Diseases 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
208000004145 Endometritis Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000005232 Glossitis Diseases 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
LRUUNMYPIBZBQH-UHFFFAOYSA-N Methazole Chemical compound O=C1N(C)C(=O)ON1C1=CC=C(Cl)C(Cl)=C1 LRUUNMYPIBZBQH-UHFFFAOYSA-N 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
241000204048 Mycoplasma hominis Species 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
241000192013 Peptoniphilus asaccharolyticus Species 0.000 description 1
241000191992 Peptostreptococcus Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
241001272996 Polyphylla fullo Species 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000008718 Pyuria Diseases 0.000 description 1
235000019484 Rapeseed oil Nutrition 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
HDDNUOWWUSULGC-UHFFFAOYSA-F S(=O)([O-])[O-].S(=O)([O-])[O-].S(=O)([O-])[O-].S(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] Chemical compound S(=O)([O-])[O-].S(=O)([O-])[O-].S(=O)([O-])[O-].S(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] HDDNUOWWUSULGC-UHFFFAOYSA-F 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
206010043945 Tongue coated Diseases 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
241000224526 Trichomonas Species 0.000 description 1
241000224527 Trichomonas vaginalis Species 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229910052936 alkali metal sulfate Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
LHZXVGBVOKGIRR-UHFFFAOYSA-N butan-2-yloxy-dihydroxy-sulfanylidene-$l^{5}-phosphane Chemical compound CCC(C)OP(O)(O)=S LHZXVGBVOKGIRR-UHFFFAOYSA-N 0.000 description 1
OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000010495 camellia oil Substances 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000001112 coagulating effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
229910001651 emery Inorganic materials 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000007046 ethoxylation reaction Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000004088 foaming agent Substances 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
238000001879 gelation Methods 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical class CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000016290 incoordination Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004914 menses Anatomy 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
WLCYBNZFNFSYSO-UHFFFAOYSA-N methyl 4-hydroxybenzoate propane-1,2,3-triol propyl 4-hydroxybenzoate Chemical compound OCC(O)CO.COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1 WLCYBNZFNFSYSO-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940078812 myristyl myristate Drugs 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
150000002790 naphthalenes Chemical class 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
229960000349 nitrofural Drugs 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
229940075643 oleth-3 Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000002892 organic cations Chemical class 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
239000008385 outer phase Substances 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229940100460 peg-100 stearate Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
231100000719 pollutant Toxicity 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920001522 polyglycol ester Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229940096992 potassium oleate Drugs 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
238000003825 pressing Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
238000011120 smear test Methods 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003784 tall oil Substances 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940044977 vaginal tablet Drugs 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000004078 waterproofing Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
235000014101 wine Nutrition 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gynecology & Obstetrics (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL90285507A 1989-06-06 1990-06-06 Sposób wytwarzania srodka do leczenia zapalenia pochwy i rzesistkowicy PL PL PL164128B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36227389A	1989-06-06	1989-06-06

Publications (2)

Publication Number	Publication Date
PL285507A1 PL285507A1 (en)	1992-01-13
PL164128B1 true PL164128B1 (pl)	1994-06-30

Family

ID=23425444

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL90285507A PL164128B1 (pl)	1989-06-06	1990-06-06	Sposób wytwarzania srodka do leczenia zapalenia pochwy i rzesistkowicy PL PL

Country Status (21)

Country	Link
EP (1)	EP0404376B1 (de)
JP (1)	JP2999820B2 (de)
KR (1)	KR0169487B1 (de)
CN (1)	CN1054507C (de)
AT (1)	ATE103176T1 (de)
AU (1)	AU635752B2 (de)
BR (1)	BR9006793A (de)
CA (1)	CA1337279C (de)
DE (1)	DE69007547T2 (de)
DK (1)	DK0404376T3 (de)
ES (1)	ES2062366T3 (de)
HU (1)	HU207795B (de)
IE (1)	IE65413B1 (de)
IL (1)	IL94619A (de)
PH (1)	PH30718A (de)
PL (1)	PL164128B1 (de)
RO (1)	RO109156B1 (de)
RU (1)	RU2032402C1 (de)
WO (1)	WO1990014832A1 (de)
YU (1)	YU47950B (de)
ZA (1)	ZA904413B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5592949A (en) *	1994-06-29	1997-01-14	Moench; Thomas R.	Device for acidic buffering and method for inactivation of pathogens
GB9610359D0 (en) *	1996-05-17	1996-07-24	Edko Trading Representation	Pharmaceutical compositions
GB9626513D0 (en) *	1996-12-20	1997-02-05	Bioglan Ireland R & D Ltd	A pharmaceutical composition
RU2154477C1 (ru) *	1998-12-10	2000-08-20	Новокузнецкий государственный институт усовершенствования врачей	Способ лечения хронического трихомониаза
RU2195945C2 (ru) *	2000-02-14	2003-01-10	Владивостокский государственный медицинский университет	Способ лечения инфекций, передаваемых половым путем
RU2195943C2 (ru) *	2000-02-14	2003-01-10	Владивостокский государственный медицинский университет	Способ лечения гонореи
US8512718B2 (en)	2000-07-03	2013-08-20	Foamix Ltd.	Pharmaceutical composition for topical application
DE10114244A1 (de) *	2001-03-22	2002-10-02	Heraeus Kulzer Gmbh & Co Kg	Antibiotikum-/Antibiotika-Zubereitung mit retardierender Wirkstofffreisetzung
IL157771A0 (en) *	2001-03-27	2004-03-28	Galen Chemicals Ltd	Intravaginal drug delivery devices for the administration of an antimicrobial agent
RU2180567C1 (ru) *	2001-05-03	2002-03-20	Новокузнецкий государственный институт усовершенствования врачей	Способ лечения хронического рецидивирующего трихомониаза
RU2212238C2 (ru) *	2001-11-05	2003-09-20	Новокузнецкий государственный институт усовершенствования врачей	Способ лечения рецидивирующего урогенитального кандидоза на фоне трихомониаза
GB0130666D0 (en) *	2001-12-21	2002-02-06	Accantla Holdings Ltd	Absorbent tampons
US6899890B2 (en) *	2002-03-20	2005-05-31	Kv Pharmaceutical Company	Bioadhesive drug delivery system
RU2221574C2 (ru) *	2002-03-21	2004-01-20	Саратовский государственный медицинский университет	Способ лечения хронического трихомонадного эндоцервицита
MXPA04010890A (es) *	2002-05-01	2005-07-14	Johnson & Johnson	Composiciones lubricantes anhidras generadoras de calor y no irritantes.
US7658941B2 (en)	2002-05-01	2010-02-09	Johnson & Johnson Consumer Companies, Inc.	Warming and nonirritating lubricant compositions and method of comparing irritation
CA2484318C (en) *	2002-05-01	2014-01-28	Mcneil-Ppc, Inc.	Warming and nonirritating lubricant antifungal gel compositions
US7695730B2 (en)	2002-05-01	2010-04-13	Mcneil-Ppc, Inc.	Warming and nonirritating lubricant compositions and method of comparing irritation
US7005408B2 (en) *	2002-05-01	2006-02-28	Mcneil-Ppc, Inc.	Warming and nonirritating lubricant compositions and method of comparing irritation
US7417013B2 (en)	2002-05-01	2008-08-26	Mcneil-Ppc, Inc.	Warming and nonirritating lubricant compositions and method of comparing irritation
US20060140984A1 (en)	2002-10-25	2006-06-29	Foamix Ltd.	Cosmetic and pharmaceutical foam
IL152486A0 (en)	2002-10-25	2003-05-29	Meir Eini	Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en)	2002-10-25	2008-06-12	Foamix Ltd.	Foam prepared from nanoemulsions and uses
US8486376B2 (en)	2002-10-25	2013-07-16	Foamix Ltd.	Moisturizing foam containing lanolin
US10117812B2 (en)	2002-10-25	2018-11-06	Foamix Pharmaceuticals Ltd.	Foamable composition combining a polar solvent and a hydrophobic carrier
US7700076B2 (en)	2002-10-25	2010-04-20	Foamix, Ltd.	Penetrating pharmaceutical foam
US9668972B2 (en)	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en)	2002-11-29	2015-12-15	Foamix Pharmaceuticals Ltd.	Antibiotic kit and composition and uses thereof
US8119150B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Non-flammable insecticide composition and uses thereof
US8900554B2 (en)	2002-10-25	2014-12-02	Foamix Pharmaceuticals Ltd.	Foamable composition and uses thereof
US9265725B2 (en)	2002-10-25	2016-02-23	Foamix Pharmaceuticals Ltd.	Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20050186142A1 (en) *	2002-10-25	2005-08-25	Foamix Ltd.	Kit and composition of imidazole with enhanced bioavailability
US7820145B2 (en)	2003-08-04	2010-10-26	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
US8119109B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Foamable compositions, kits and methods for hyperhidrosis
US7704518B2 (en)	2003-08-04	2010-04-27	Foamix, Ltd.	Foamable vehicle and pharmaceutical compositions thereof
US7575739B2 (en)	2003-04-28	2009-08-18	Foamix Ltd.	Foamable iodine composition
RU2240781C1 (ru) *	2003-06-05	2004-11-27	Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии	Способ лечения воспалительных процессов вульвы и влагалища
EP1635847B1 (de) *	2003-06-13	2019-07-31	IDH Holding ApS	Behandlung von symptomen im zusammenhang mit bakterieller vaginose
RU2236851C1 (ru) *	2003-06-16	2004-09-27	Красноярская государственная медицинская академия	Способ местного лечения бактериального вагиноза
US8795693B2 (en)	2003-08-04	2014-08-05	Foamix Ltd.	Compositions with modulating agents
US8486374B2 (en)	2003-08-04	2013-07-16	Foamix Ltd.	Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20060140990A1 (en) *	2003-09-19	2006-06-29	Drugtech Corporation	Composition for topical treatment of mixed vaginal infections
WO2005027807A1 (en)	2003-09-19	2005-03-31	Drugtech Corporation	Pharmaceutical delivery system
RU2249821C1 (ru) *	2004-04-27	2005-04-10	Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского Министерства здравоохранения Российской Федерации"	Способ оценки микробиоценоза влагалища
MXPA04007681A (es) *	2004-07-08	2006-01-12	Drugtech Corp	Sistema de liberacion.
RU2275918C1 (ru) *	2005-01-11	2006-05-10	ГОУ ВПО "Красноярская государственная медицинская академия Министерства здравоохранения РФ"	Способ лечения хронического сальпингоофорита
US7851419B2 (en)	2005-09-12	2010-12-14	Nawaz Ahmad	Substantially anhydrous sprayable personal lubricant
US20070059250A1 (en) *	2005-09-12	2007-03-15	Nawaz Ahmad	Sprayable personal lubricant
WO2007079389A2 (en) *	2006-01-05	2007-07-12	Drugtech Corporation	Composition and method of use thereof
KR20080083190A (ko) *	2006-01-05	2008-09-16	드러그테크 코포레이션	외음질 표면에 생체접착을 위한 약물 전달 시스템
US20080260655A1 (en)	2006-11-14	2008-10-23	Dov Tamarkin	Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
RU2356535C2 (ru) *	2007-07-23	2009-05-27	Закрытое Акционерное Общество "Биокад"	Суппозитории комбинированного действия для лечения инфекционных гинекологических заболеваний (варианты)
US8636982B2 (en)	2007-08-07	2014-01-28	Foamix Ltd.	Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en)	2007-11-30	2009-06-04	Foamix Ltd.	Foam containing benzoyl peroxide
WO2010041141A2 (en)	2008-10-07	2010-04-15	Foamix Ltd.	Oil-based foamable carriers and formulations
WO2009072007A2 (en)	2007-12-07	2009-06-11	Foamix Ltd.	Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
AU2009205314A1 (en)	2008-01-14	2009-07-23	Foamix Ltd.	Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
EP2385821B1 (de) *	2009-01-09	2016-08-31	Egis Gyógyszergyár Zrt.	Verbesserte pharmazeutische formulierung
US20120087872A1 (en)	2009-04-28	2012-04-12	Foamix Ltd.	Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
CA2769677A1 (en)	2009-07-29	2011-02-03	Foamix Ltd.	Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en)	2009-07-29	2011-02-03	Foamix Ltd.	Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en)	2009-10-02	2017-12-26	Foamix Pharmaceuticals Ltd.	Methods for accelerated return of skin integrity and for the treatment of impetigo
AU2010302350B2 (en)	2009-10-02	2015-06-18	Journey Medical Corporation	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US12661407B2 (en)	2010-04-08	2026-06-23	Journey Medical Corporation	Compositions, gels and foams with rheology modulators and uses thereof
RU2428173C1 (ru) *	2010-06-03	2011-09-10	Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР")	Фармацевтическая композиция для лечения заболеваний нижнего отдела мочеполовой системы
AU2012275292B2 (en)	2011-06-28	2015-11-12	Chemo Research, S.L.	High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis
EP3013368A1 (de)	2013-06-25	2016-05-04	Mission Pharmacal Company	Neuartige formulierungen zur behandlung von vaginalen erkrankungen
MX2020012139A (es)	2016-09-08	2021-01-29	Vyne Pharmaceuticals Inc	Composiciones y metodos para tratar rosacea y acne.
RU2730021C1 (ru) *	2019-10-08	2020-08-14	Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА"	Средство местного применения для лечения инфекционных вагинитов
CN112773780A (zh) *	2019-11-11	2021-05-11	深圳优丽康生物技术有限公司	一种阴道外阴用组合物及其用途
RU2726123C1 (ru) *	2019-12-20	2020-07-09	Федеральное государственное бюджетное учреждение науки Оренбургский федеральный исследовательский центр Уральского отделения Российской академии наук	Способ лечения трихомониаза у женщин
US11529346B2 (en) *	2020-06-18	2022-12-20	National Medical Supply, LLC	Vaginal gel
US20210401879A1 (en) *	2020-06-30	2021-12-30	Vireo Systems, Inc.	Compositions for controlling odor and itch and methods of and devices for administering same
CN115737551B (zh) *	2022-12-06	2025-08-05	天津市保灵动物保健品有限公司	一种氟苯尼考甲硝唑滴耳液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3070778D1 (en) *	1979-08-11	1985-07-25	Bayer Ag	Antimycotic agents with enhanced release of the active ingredients
US4602040A (en) *	1983-04-18	1986-07-22	Warner-Lambert Company	Meclofenamic acid topical pharmaceutical composition
US4837378A (en) *	1986-01-15	1989-06-06	Curatek Pharmaceuticals, Inc.	Topical metronidazole formulations and therapeutic uses thereof
GB8607159D0 (en) *	1986-03-22	1986-04-30	Smith & Nephew Ass	Pharmaceutical composition
SE8603338D0 (sv) *	1986-08-07	1986-08-07	Bjorn Andersch	Medel for behandling av tillstand i slidan

1989
- 1989-09-28 CA CA000613846A patent/CA1337279C/en not_active Expired - Lifetime
1990
- 1990-06-04 HU HU904720A patent/HU207795B/hu unknown
- 1990-06-04 WO PCT/US1990/003195 patent/WO1990014832A1/en not_active Ceased
- 1990-06-04 RO RO146869A patent/RO109156B1/ro unknown
- 1990-06-04 KR KR1019910700140A patent/KR0169487B1/ko not_active Expired - Fee Related
- 1990-06-04 BR BR909006793A patent/BR9006793A/pt not_active Application Discontinuation
- 1990-06-04 JP JP2508862A patent/JP2999820B2/ja not_active Expired - Fee Related
- 1990-06-04 AU AU58294/90A patent/AU635752B2/en not_active Expired
- 1990-06-05 EP EP90306026A patent/EP0404376B1/de not_active Expired - Lifetime
- 1990-06-05 AT AT90306026T patent/ATE103176T1/de not_active IP Right Cessation
- 1990-06-05 DK DK90306026.7T patent/DK0404376T3/da active
- 1990-06-05 PH PH40620A patent/PH30718A/en unknown
- 1990-06-05 ES ES90306026T patent/ES2062366T3/es not_active Expired - Lifetime
- 1990-06-05 DE DE69007547T patent/DE69007547T2/de not_active Expired - Lifetime
- 1990-06-05 CN CN90104911A patent/CN1054507C/zh not_active Expired - Fee Related
- 1990-06-05 IE IE201190A patent/IE65413B1/en not_active IP Right Cessation
- 1990-06-05 IL IL9461990A patent/IL94619A/en unknown
- 1990-06-06 PL PL90285507A patent/PL164128B1/pl unknown
- 1990-06-06 YU YU170090A patent/YU47950B/sh unknown
- 1990-06-07 ZA ZA904413A patent/ZA904413B/xx unknown
1991
- 1991-02-05 RU SU914894747A patent/RU2032402C1/ru active

Also Published As

Publication number	Publication date
HUT56490A (en)	1991-09-30
DE69007547T2 (de)	1994-07-14
CN1054507C (zh)	2000-07-19
HU904720D0 (en)	1991-07-29
YU47950B (sh)	1996-07-24
YU170090A (sh)	1994-04-05
CN1049101A (zh)	1991-02-13
KR920700032A (ko)	1992-02-19
ZA904413B (en)	1991-04-24
JPH04500365A (ja)	1992-01-23
AU5829490A (en)	1991-01-07
RO109156B1 (ro)	1994-12-30
KR0169487B1 (ko)	1999-01-15
IL94619A0 (en)	1991-04-15
EP0404376A3 (de)	1991-06-05
BR9006793A (pt)	1991-08-06
RU2032402C1 (ru)	1995-04-10
EP0404376A2 (de)	1990-12-27
CA1337279C (en)	1995-10-10
ES2062366T3 (es)	1994-12-16
AU635752B2 (en)	1993-04-01
EP0404376B1 (de)	1994-03-23
DK0404376T3 (da)	1994-05-24
WO1990014832A1 (en)	1990-12-13
IE65413B1 (en)	1995-10-18
IE902011L (en)	1990-12-06
HU207795B (en)	1993-06-28
PH30718A (en)	1997-09-23
PL285507A1 (en)	1992-01-13
DE69007547D1 (de)	1994-04-28
ATE103176T1 (de)	1994-04-15
IL94619A (en)	1995-01-24
JP2999820B2 (ja)	2000-01-17

Publication	Publication Date	Title
RU2032402C1 (ru)	1995-04-10	Композиция для лечения вагинита и способ его лечения
US5536743A (en)	1996-07-16	Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US7285517B2 (en)	2007-10-23	Warming and nonirritating lubricant compositions and method of comparing irritation
US20090030060A1 (en)	2009-01-29	Intravaginal treatment of vaginal infections with metronidazole compositions
US20070287714A1 (en)	2007-12-13	Warming and Nonirritating Lubricant Compositions and Method of Comparing Irritation
BRPI0620905A2 (pt)	2011-11-29	uso de uma composição farmacêutica, composição farmacêutica e sistema de distribuição antibacteriano e antifúngico vaginal
ES2891754T3 (es)	2022-01-31	Formulaciones y tratamientos tópicos
US20240122842A1 (en)	2024-04-18	System, product and method for maintaining the vaginal microbiome
JP2011530541A (ja)	2011-12-22	粘膜付着性組成物およびそれらの使用
US7456207B2 (en)	2008-11-25	Vaginal pharmaceutical compositions and methods for preparing them
US20040185065A1 (en)	2004-09-23	Warming and nonirritating lubricant compositions and method of comparing irritation
EP3501507B1 (de)	2020-07-15	Macrogole zur behandlung der schleimhäute und therapeutische verwendungen davon
JP2007077152A (ja)	2007-03-29	膣のｐＨを低下させるための組成物および方法
JP2007077150A (ja)	2007-03-29	酸−酸緩衝系を含有する無水組成物
RU2498806C2 (ru)	2013-11-20	Фармацевтический состав для лечения инфекционных воспалительных заболеваний в гинекологии и способ его получения
ES2983432T3 (es)	2024-10-23	Composición para el tratamiento y/o la prevención de la vestibulodinia
BR102013005373A2 (pt)	2014-10-29	Forma farmacêutica semi-sólida e seus usos apra prevenção e/ou tratamento das atrofias vaginais